COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTORS

The present disclosure relates to bifunctional compounds that serve as degraders (and/or inhibitors) of the estrogen receptor (target protein). In the present disclosure, the bifunctional compounds, which contain a target protein (estrogen receptor) binding moiety and a E3 ubiquitin ligase (CRBN) bi...

Full description

Saved in:
Bibliographic Details
Main Authors Kang, Borui, Choi, Hyunjung, Park, Bongsu, Kim, HongJoong, Jung, Hunsoon, Peng, Xianyou, Wang, Guangdi
Format Patent
LanguageEnglish
Published 03.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure relates to bifunctional compounds that serve as degraders (and/or inhibitors) of the estrogen receptor (target protein). In the present disclosure, the bifunctional compounds, which contain a target protein (estrogen receptor) binding moiety and a E3 ubiquitin ligase (CRBN) binding moiety, are directed to bind to both estrogen receptor and CRBN, such that the ER is placed in close proximity to the E3 ligase to mediate ubiquitylation of the target protein followed by degradation of the target protein by the proteasome. The present disclosure provides methods for synthesizing the herein disclosed bifunctional compounds, and their pharmacological activities associated with degradation or inhibition of the target protein. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.
Bibliography:Application Number: US202217716051